KOBV Portal

Hits per page

hits 1 - 10 | 167,816 hits

Sorting

Online Resource

Supplementary material 9 from: Saarela JM, Bull RD, Paradis MJ, Ebata SN, Peterson PM, Soreng RJ, Paszko B (2017) Molecular phylogenetics of cool-season grasses in the subtribes Agrostidinae, Anthoxanthinae, Aveninae, Brizinae, Calothecinae, Koeleriinae and Phalaridinae (Poaceae, Pooideae, Poeae, Poeae chloroplast group 1). PhytoKeys 87: 1-139. https://doi.org/10.3897/phytokeys.87.12774

Saarela, Jeffery M. ; Bull, Roger D. ; Paradis, Michel J. ; [et al.]

Pensoft Publishers ; 2017

In: PhytoKeys Vol. 87 ( 2017-10-09), p. 1-139

add to watchlist on the watchlist

Details

In: PhytoKeys, Pensoft Publishers, Vol. 87 ( 2017-10-09), p. 1-139

Type of Medium: Online Resource

ISSN: 1314-2003 , 1314-2011

URL: Article

DOI: 10.3897/phytokeys.87.12774

DOI: 10.3897/phytokeys.87.12774.figure1

DOI: 10.3897/phytokeys.87.12774.figure10

DOI: 10.3897/phytokeys.87.12774.figure11

DOI: 10.3897/phytokeys.87.12774.figure12

DOI: 10.3897/phytokeys.87.12774.figure13

DOI: 10.3897/phytokeys.87.12774.figure14

DOI: 10.3897/phytokeys.87.12774.figure15

DOI: 10.3897/phytokeys.87.12774.figure16

DOI: 10.3897/phytokeys.87.12774.figure17

DOI: 10.3897/phytokeys.87.12774.figure18

DOI: 10.3897/phytokeys.87.12774.figure19

DOI: 10.3897/phytokeys.87.12774.figure2

DOI: 10.3897/phytokeys.87.12774.figure20

DOI: 10.3897/phytokeys.87.12774.figure21

DOI: 10.3897/phytokeys.87.12774.figure22

DOI: 10.3897/phytokeys.87.12774.figure23

DOI: 10.3897/phytokeys.87.12774.figure24

DOI: 10.3897/phytokeys.87.12774.figure3

DOI: 10.3897/phytokeys.87.12774.figure4

DOI: 10.3897/phytokeys.87.12774.figure5

DOI: 10.3897/phytokeys.87.12774.figure6

DOI: 10.3897/phytokeys.87.12774.figure7

DOI: 10.3897/phytokeys.87.12774.figure8

DOI: 10.3897/phytokeys.87.12774.figure9

DOI: 10.3897/phytokeys.87.12774.suppl1

DOI: 10.3897/phytokeys.87.12774.suppl10

DOI: 10.3897/phytokeys.87.12774.suppl11

DOI: 10.3897/phytokeys.87.12774.suppl12

DOI: 10.3897/phytokeys.87.12774.suppl13

DOI: 10.3897/phytokeys.87.12774.suppl14

DOI: 10.3897/phytokeys.87.12774.suppl15

DOI: 10.3897/phytokeys.87.12774.suppl16

DOI: 10.3897/phytokeys.87.12774.suppl17

DOI: 10.3897/phytokeys.87.12774.suppl18

DOI: 10.3897/phytokeys.87.12774.suppl19

DOI: 10.3897/phytokeys.87.12774.suppl2

DOI: 10.3897/phytokeys.87.12774.suppl20

DOI: 10.3897/phytokeys.87.12774.suppl3

DOI: 10.3897/phytokeys.87.12774.suppl4

DOI: 10.3897/phytokeys.87.12774.suppl5

DOI: 10.3897/phytokeys.87.12774.suppl6

DOI: 10.3897/phytokeys.87.12774.suppl7

DOI: 10.3897/phytokeys.87.12774.suppl8

DOI: 10.3897/phytokeys.87.12774.suppl9

Language: Unknown

Publisher: Pensoft Publishers

Publication Date: 2017

detail.hit.zdb_id: 2579891-1

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

Online Resource

The James Webb Space Telescope Mission

Gardner, Jonathan P. ; Mather, John C. ; Abbott, Randy ; [et al.]

IOP Publishing ; 2023

In: Publications of the Astronomical Society of the Pacific Vol. 135, No. 1048 ( 2023-06-01), p. 068001-

add to watchlist on the watchlist

Details

In: Publications of the Astronomical Society of the Pacific, IOP Publishing, Vol. 135, No. 1048 ( 2023-06-01), p. 068001-

Abstract: Twenty-six years ago a small committee report, building on earlier studies, expounded a compelling and poetic vision for the future of astronomy, calling for an infrared-optimized space telescope with an aperture of at least 4 m. With the support of their governments in the US, Europe, and Canada, 20,000 people realized that vision as the 6.5 m James Webb Space Telescope. A generation of astronomers will celebrate their accomplishments for the life of the mission, potentially as long as 20 yr, and beyond. This report and the scientific discoveries that follow are extended thank-you notes to the 20,000 team members. The telescope is working perfectly, with much better image quality than expected. In this and accompanying papers, we give a brief history, describe the observatory, outline its objectives and current observing program, and discuss the inventions and people who made it possible. We cite detailed reports on the design and the measured performance on orbit.

Type of Medium: Online Resource

ISSN: 0004-6280 , 1538-3873

URL: Article

DOI: 10.1088/1538-3873/acd1b5

Language: Unknown

Publisher: IOP Publishing

Publication Date: 2023

detail.hit.zdb_id: 2003100-2

detail.hit.zdb_id: 2207655-4

SSG: 16,12

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

Online Resource

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

Verma, Subodh ; Bhatt, Deepak L. ; Steg, Ph. Gabriel ; [et al.]

Ovid Technologies (Wolters Kluwer Health) ; 2021

In: Circulation Vol. 144, No. 23 ( 2021-12-07), p. 1845-1855

add to watchlist on the watchlist

Details

In: Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 144, No. 23 ( 2021-12-07), p. 1845-1855

Abstract: Despite advances in surgery and pharmacotherapy, there remains significant residual ischemic risk after coronary artery bypass grafting surgery. Methods: In REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), a multicenter, placebo-controlled, double-blind trial, statin-treated patients with controlled low-density lipoprotein cholesterol and mild to moderate hypertriglyceridemia were randomized to 4 g daily of icosapent ethyl or placebo. They experienced a 25% reduction in risk of a primary efficacy end point (composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina) and a 26% reduction in risk of a key secondary efficacy end point (composite of cardiovascular death, myocardial infarction, or stroke) when compared with placebo. The current analysis reports on the subgroup of patients from the trial with a history of coronary artery bypass grafting. Results: Of the 8179 patients randomized in REDUCE-IT, a total of 1837 (22.5%) had a history of coronary artery bypass grafting, with 897 patients randomized to icosapent ethyl and 940 to placebo. Baseline characteristics were similar between treatment groups. Randomization to icosapent ethyl was associated with a significant reduction in the primary end point (hazard ratio [HR], 0.76 [95% CI, 0.63–0.92] ; P =0.004), in the key secondary end point (HR, 0.69 [95% CI, 0.56–0.87]; P =0.001), and in total (first plus subsequent or recurrent) ischemic events (rate ratio, 0.64 [95% CI, 0.50–0.81]; P =0.0002) compared with placebo. This yielded an absolute risk reduction of 6.2% (95% CI, 2.3%–10.2%) in first events, with a number needed to treat of 16 (95% CI, 10–44) during a median follow-up time of 4.8 years. Safety findings were similar to the overall study: beyond an increased rate of atrial fibrillation/flutter requiring hospitalization for at least 24 hours (5.0% vs 3.1%; P =0.03) and a nonsignificant increase in bleeding, occurrences of adverse events were comparable between groups. Conclusions: In REDUCE-IT patients with a history of coronary artery bypass grafting, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01492361.

Type of Medium: Online Resource

ISSN: 0009-7322 , 1524-4539

URL: Article

DOI: 10.1161/CIRCULATIONAHA.121.056290

Language: English

Publisher: Ovid Technologies (Wolters Kluwer Health)

Publication Date: 2021

detail.hit.zdb_id: 1466401-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

Online Resource

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Schwartz, Gregory G. ; Szarek, Michael ; Bittner, Vera A. ; [et al.]

American Diabetes Association ; 2021

In: Diabetes Care Vol. 44, No. 5 ( 2021-05-01), p. 1219-1227

add to watchlist on the watchlist

Details

In: Diabetes Care, American Diabetes Association, Vol. 44, No. 5 ( 2021-05-01), p. 1219-1227

Abstract: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor. RESEARCH DESIGN AND METHODS In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data. RESULTS Among 13,480 patients without diabetes at baseline, 1,324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated with hazard ratio 1.04 (95% CI 1.02−1.06, P & lt; 0.001) for incident type 2 diabetes. Alirocumab reduced lipoprotein(a) by a median 23.2% with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes (hazard ratio 0.95, 95% CI 0.85–1.05). At low baseline lipoprotein(a) levels, alirocumab tended to reduce incident type 2 diabetes, while at high baseline lipoprotein(a) alirocumab tended to increase incident type 2 diabetes compared with placebo (treatment–baseline lipoprotein(a) interaction P = 0.006). In the alirocumab group, a 10 mg/dL decrease in lipoprotein(a) from baseline was associated with hazard ratio 1.07 (95% CI 1.03−1.12; P = 0.0002) for incident type 2 diabetes. CONCLUSIONS In patients with acute coronary syndrome, baseline lipoprotein(a) concentration associated inversely with incident type 2 diabetes. Alirocumab had neutral overall effect on incident type 2 diabetes. However, treatment-related reductions in lipoprotein(a), more pronounced from high baseline levels, were associated with increased risk of incident type 2 diabetes. Whether these findings pertain to other therapies that reduce lipoprotein(a) is undetermined.

Type of Medium: Online Resource

ISSN: 0149-5992 , 1935-5548

URL: Article

DOI: 10.2337/dc20-2842

Language: English

Publisher: American Diabetes Association

Publication Date: 2021

detail.hit.zdb_id: 1490520-6

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

Online Resource

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, Kausik K ; Colhoun, Helen M ; Szarek, Michael ; [et al.]

Elsevier BV ; 2019

In: The Lancet Diabetes & Endocrinology Vol. 7, No. 8 ( 2019-08), p. 618-628

add to watchlist on the watchlist

Details

In: The Lancet Diabetes & Endocrinology, Elsevier BV, Vol. 7, No. 8 ( 2019-08), p. 618-628

Type of Medium: Online Resource

ISSN: 2213-8587

URL: Article

DOI: 10.1016/S2213-8587(19)30158-5

Language: English

Publisher: Elsevier BV

Publication Date: 2019

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Online Resource

Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

Jampol, Lee M. ; Glassman, Adam R. ; Liu, Danni ; [et al.]

Elsevier BV ; 2018

In: Ophthalmology Vol. 125, No. 7 ( 2018-07), p. 1054-1063

add to watchlist on the watchlist

Details

In: Ophthalmology, Elsevier BV, Vol. 125, No. 7 ( 2018-07), p. 1054-1063

Type of Medium: Online Resource

ISSN: 0161-6420

URL: Article

DOI: 10.1016/j.ophtha.2018.01.019

RVK:

XA 10000

Language: English

Publisher: Elsevier BV

Publication Date: 2018

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Online Resource

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two : National Harbor, MD, USA. 9-13 November 2016

Ager, Casey ; Reilley, Matthew ; Nicholas, Courtney ; [et al.]

BMJ ; 2016

In: Journal for ImmunoTherapy of Cancer Vol. 4, No. S1 ( 2016-11)

add to watchlist on the watchlist

Details

In: Journal for ImmunoTherapy of Cancer, BMJ, Vol. 4, No. S1 ( 2016-11)

Type of Medium: Online Resource

ISSN: 2051-1426

URL: Article

DOI: 10.1186/s40425-016-0173-6

Language: English

Publisher: BMJ

Publication Date: 2016

detail.hit.zdb_id: 2719863-7

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

Online Resource

Abstracts of papers presented at the 81st annual meeting of The Potato Association of America Charlottetown, P.E.I., Canada August 3 – 7, 1997

Ali-Khan, S. T. ; Hetner, C. ; Ladislav, L. ; [et al.]

Springer Science and Business Media LLC ; 1997

In: American Potato Journal Vol. 74, No. 6 ( 1997-11), p. 415-477

add to watchlist on the watchlist

Details

In: American Potato Journal, Springer Science and Business Media LLC, Vol. 74, No. 6 ( 1997-11), p. 415-477

Type of Medium: Online Resource

ISSN: 0003-0589 , 1874-9380

URL: Article

DOI: 10.1007/BF02852782

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 1997

detail.hit.zdb_id: 2395546-6

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

Online Resource

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, Emil ; Steg, P. Gabriel ; Szarek, Michael ; [et al.]

Ovid Technologies (Wolters Kluwer Health) ; 2022

In: Circulation Vol. 146, No. 9 ( 2022-08-30), p. 657-672

add to watchlist on the watchlist

Details

In: Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 146, No. 9 ( 2022-08-30), p. 657-672

Abstract: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. Methods: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy. Primary outcome was major adverse cardiovascular events (MACE; coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, hospitalization for unstable angina). Associations between baseline apoB or apoB at 4 months and MACE were assessed in adjusted Cox proportional hazards and propensity score–matched models. Results: Median follow-up was 2.8 years. In proportional hazards analysis in the placebo group, MACE incidence increased across increasing baseline apoB strata (3.2 [95% CI, 2.9–3.6], 4.0 [95% CI, 3.6–4.5] , and 5.5 [95% CI, 5.0–6.1] events per 100 patient-years in strata 〈 75, 75– 〈 90, ≥90 mg/dL, respectively; P trend 〈 0.0001) and after adjustment for low-density lipoprotein cholesterol ( P trend =0.035). Higher baseline apoB stratum was associated with greater relative ( P trend 〈 0.0001) and absolute reduction in MACE with alirocumab versus placebo. In the alirocumab group, the incidence of MACE after month 4 decreased monotonically across decreasing achieved apoB strata (4.26 [95% CI, 3.78–4.79], 3.09 [95% CI, 2.69–3.54] , and 2.41 [95% CI, 2.11–2.76] events per 100 patient-years in strata ≥50, 〉 35– 〈 50, and ≤35 mg/dL, respectively). Compared with propensity score–matched patients from the placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved apoB strata. Achieved apoB was predictive of MACE after adjustment for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol but not vice versa. Conclusions: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACE increased across baseline apoB strata. Alirocumab reduced MACE across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACE, even after accounting for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of apoB levels as low as ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01663402.

Type of Medium: Online Resource

ISSN: 0009-7322 , 1524-4539

URL: Article

DOI: 10.1161/CIRCULATIONAHA.121.057807

Language: English

Publisher: Ovid Technologies (Wolters Kluwer Health)

Publication Date: 2022

detail.hit.zdb_id: 1466401-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

Online Resource

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, Gregory G. ; Szarek, Michael ; Bittner, Vera A. ; [et al.]

Elsevier BV ; 2021

In: Journal of the American College of Cardiology Vol. 78, No. 5 ( 2021-08), p. 421-433

add to watchlist on the watchlist

Details

In: Journal of the American College of Cardiology, Elsevier BV, Vol. 78, No. 5 ( 2021-08), p. 421-433

Type of Medium: Online Resource

ISSN: 0735-1097

URL: Article

DOI: 10.1016/j.jacc.2021.04.102

RVK:

XA 17760

Language: English

Publisher: Elsevier BV

Publication Date: 2021

detail.hit.zdb_id: 1468327-1

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

BTU Cottbus

Wissenschaftspark Albert Einstein

EUV Frankfurt

TH Wildau

FH Potsdam

hits 1 - 10 | 167,816 hits

Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.

Kooperativer Bibliotheksverbund

Berlin Brandenburg